Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Monopar Therapeutics
Report date September 30, 2026 · Filed October 02, 2026
Section 16 reporting ended · disclosed 2025-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,724 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 9,801 · Balance 109,068 F1: Represents shares acquired on vesting and settlement of restricted stock units. Row 2 · 2026-09-30 · Tax withholding · Disposed 4,344 · Balance 104,724 F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 83,602 |
Reported balance
After 2026-09-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-30 · Exercise / conversion · Disposed 9,801 · Balance 83,602 F1: Represents shares acquired on vesting and settlement of restricted stock units. F4: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 62,815 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 62,815 F3: Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired on vesting and settlement of restricted stock units.
F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3: Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
F4: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F6: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2024 Filed Jul 2, 2024 22:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 24,476 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-022023 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,606.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| May 28, 2024 Filed May 30, 2024 22:10 UTC | Monopar Therapeutics MNPR · Entity 5152 | OtherStock Options · Derivative | 84,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-018775 · rdgdoc.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,000 shares Expires 2026-04-03 F4 · derivative.exercise_date: Reflects options to purchase up to 84,000 shares of common stock granted to Dr. Robinson on April 4, 2016 for his services as a director and officer of Monopar Therapeutics. The options vested 50% upon grant date, 25% upon the 6-month anniversary of grant date, and 25% upon the 1-year anniversary of grant date. Read SEC document |
| May 28, 2024 Filed May 30, 2024 22:10 UTC | Monopar Therapeutics MNPR · Entity 5152 | OtherCommon Stock | 84,000 | $0.00 | $84.00 |
DisclosureSEC source: 0001437749-24-018775 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,130.8 F1 · shares: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 00:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 24,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-010721 · rdgdoc.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,811 Underlying: Common Stock · 24,474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F5 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 00:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 7,172 | $0.68 | $4,884.13 |
DisclosureSEC source: 0001437749-24-010721 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,130.8 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 00:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 24,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-010721 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,302.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| January 01, 2024 Filed Jan 4, 2024 00:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 6,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-000482 · rdgdoc.xml · derivative · entry 10 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,285 Underlying: Common Stock · 6,724 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F8 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F8 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| January 01, 2024 Filed Jan 4, 2024 00:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,327 | $0.34 | $791.65 |
DisclosureSEC source: 0001437749-24-000482 · rdgdoc.xml · nonDerivative · entry 6 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,828.8 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| January 01, 2024 Filed Jan 4, 2024 00:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 6,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-000482 · rdgdoc.xml · nonDerivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,155.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 24,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-000482 · rdgdoc.xml · derivative · entry 9 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,009 Underlying: Common Stock · 24,474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F5 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 8,469 | $0.34 | $2,881.15 |
DisclosureSEC source: 0001437749-24-000482 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,431.8 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 24,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-000482 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,900.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:37 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 24,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-027588 · rdgdoc.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,483 Underlying: Common Stock · 24,474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:37 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 7,172 | $0.62 | $4,445.92 |
DisclosureSEC source: 0001437749-23-027588 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,426.8 F6 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 23:37 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 24,474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-027588 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,598.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 35,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-019257 · rdgdoc.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,957 Underlying: Common Stock · 35,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 10,269 | $0.86 | $8,780.00 |
DisclosureSEC source: 0001437749-23-019257 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,124.8 F6 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 22:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 35,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-019257 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,393.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:17 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 13,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-009332 · rdgdoc.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,996 Underlying: Common Stock · 13,911 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:17 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 4,286 | $1.39 | $5,957.54 |
DisclosureSEC source: 0001437749-23-009332 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,354.8 F6 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:17 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 13,911 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-009332 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,640.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:49 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 169,012 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002518 · rdgdoc.xml · derivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,907 Underlying: Common Stock · 169,012 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2023 and 3/48ths per quarter thereafter (September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, December 31, 2026) F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2023 and 3/48ths per quarter thereafter (September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, December 31, 2026) Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:49 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 221,839 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001437749-23-002518 · rdgdoc.xml · derivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,839 Underlying: Common Stock · 221,839 shares Expires 2033-02-01 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2023 and 1/48th per month thereafter. Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 20:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 6,723 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000160 · rdgdoc.xml · derivative · entry 10 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,724 Underlying: Common Stock · 6,723 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F6 · derivative.exercise_date: On January 31, 2020, the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On January 31, 2020, the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 20:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,327 | $2.37 | $5,514.99 |
DisclosureSEC source: 0001437749-23-000160 · rdgdoc.xml · nonDerivative · entry 6 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,729.8 Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 20:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 6,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000160 · rdgdoc.xml · nonDerivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,056.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 20:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 13,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000160 · rdgdoc.xml · derivative · entry 9 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,171 Underlying: Common Stock · 13,912 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 20:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 4,814 | $2.37 | $11,409.18 |
DisclosureSEC source: 0001437749-23-000160 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,333.8 Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 20:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 13,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000160 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,147.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:55 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 13,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-013280 · section16.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,530 Underlying: Common Stock · 13,911 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:55 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 4,077 | $1.52 | $6,197.04 |
DisclosureSEC source: 0001654954-22-013280 · section16.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,235.8 Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 23:55 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 13,911 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-013280 · section16.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,312.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 23,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-009138 · section16.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,441 Underlying: Common Stock · 23,882 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 6,999 | $2.30 | $16,090.70 |
DisclosureSEC source: 0001654954-22-009138 · section16.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,401.8 Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 23,882 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-009138 · section16.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,400.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 3,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-004491 · section16.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,323 Underlying: Common Stock · 3,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,155 | $2.55 | $2,945.25 |
DisclosureSEC source: 0001654954-22-004491 · section16.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,518.8 Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 3,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-004491 · section16.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,673.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:37 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 159,522 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-001173 · section16.xml · derivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,264 Underlying: Common Stock · 159,522 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025) F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025) Read SEC document |
| February 02, 2022 Filed Feb 5, 2022 00:37 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 211,018 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001654954-22-001173 · section16.xml · derivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,018 Underlying: Common Stock · 211,018 shares Expires 2032-02-01 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 19:17 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 6,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-000126 · section16.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,447 Underlying: Common Stock · 6,724 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 19:17 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,327 | $3.21 | $7,469.67 |
DisclosureSEC source: 0001654954-22-000126 · section16.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,732.8 Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 19:17 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 6,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-000126 · section16.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,059.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 19:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 3,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-000124 · section16.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,295 Underlying: Common Stock · 3,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 19:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,364 | $3.21 | $4,378.44 |
DisclosureSEC source: 0001654954-22-000124 · section16.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,335.8 Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 19:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 3,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-000124 · section16.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,699.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:24 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 3,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-010715 · section16.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,236 Underlying: Common Stock · 3,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:24 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,155 | $4.87 | $5,624.85 |
DisclosureSEC source: 0001654954-21-010715 · section16.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,758.8 Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:24 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 3,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-010715 · section16.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,913.8 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:10 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 7,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-007593 · section16.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,177 Underlying: Common Stock · 7,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.